Artivion, Inc.

NYSE:AORT Stock Report

Market Cap: US$1.2b

Artivion Management

Management criteria checks 4/4

Artivion's CEO is Pat Mackin, appointed in Sep 2014, has a tenure of 10.17 years. total yearly compensation is $3.18M, comprised of 24.4% salary and 75.6% bonuses, including company stock and options. directly owns 1.59% of the company’s shares, worth $18.93M. The average tenure of the management team and the board of directors is 4.3 years and 8.1 years respectively.

Key information

Pat Mackin

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage24.4%
CEO tenure10.2yrs
CEO ownership1.6%
Management average tenure4.3yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

When Should You Buy Artivion, Inc. (NYSE:AORT)?

Nov 07
When Should You Buy Artivion, Inc. (NYSE:AORT)?

Returns At Artivion (NYSE:AORT) Are On The Way Up

Sep 28
Returns At Artivion (NYSE:AORT) Are On The Way Up

Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Sep 06
Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Is Artivion (NYSE:AORT) A Risky Investment?

Jun 28
Is Artivion (NYSE:AORT) A Risky Investment?

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Jun 21

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 08
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jan 13
Is Artivion (NYSE:AORT) Using Too Much Debt?

Artivion Stock: A First Assessment

Dec 27

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23
Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09
Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Dec 18

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Sep 29
Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Sep 27

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Aug 04

CEO Compensation Analysis

How has Pat Mackin's remuneration changed compared to Artivion's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$842k

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$3mUS$776k

-US$31m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$7mUS$750k

-US$19m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$5mUS$728k

-US$15m

Sep 30 2021n/an/a

US$2m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$3mUS$606k

-US$17m

Sep 30 2020n/an/a

-US$14m

Jun 30 2020n/an/a

-US$11m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$6mUS$689k

US$2m

Sep 30 2019n/an/a

US$2m

Jun 30 2019n/an/a

US$3m

Mar 31 2019n/an/a

US$709k

Dec 31 2018US$3mUS$660k

-US$3m

Sep 30 2018n/an/a

-US$5m

Jun 30 2018n/an/a

-US$5m

Mar 31 2018n/an/a

-US$2m

Dec 31 2017US$3mUS$640k

US$4m

Compensation vs Market: Pat's total compensation ($USD3.18M) is about average for companies of similar size in the US market ($USD3.18M).

Compensation vs Earnings: Pat's compensation has been consistent with company performance over the past year.

CEO

Pat Mackin (57 yo)

10.2yrs

Tenure

US$3,176,413

Compensation

Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of Artivion, Inc. (formerly known as CryoLife, Inc.) since September 02, 2014 and has been its Chairman since...

Leadership Team

NamePositionTenureCompensationOwnership
James Mackin
Chairman10.2yrsUS$3.18m1.59%
$ 18.9m
Lance Berry
Executive VP of Financeless than a yearUS$1.64m0.19%
$ 2.2m
Amy Horton
VP & Chief Accounting Officer18.3yrsUS$1.06m0.33%
$ 4.0m
Jean Holloway
Senior VP9.6yrsUS$993.72k0.39%
$ 4.6m
John Davis
Senior VP & Chief Commercial Officerless than a yearUS$953.41k0.38%
$ 4.5m
Matthew Getz
VP of Human Resources & Chief Human Resources Officer5.3yrsno data0.081%
$ 969.2k
Marshall Stanton
Senior VP of Clinical Research & Chief Medical Officer3.7yrsUS$1.61m0.20%
$ 2.4m
Robert Thomson
Vice President of Research & Development1.4yrsno data0.032%
$ 377.6k
Florian Tyrs
Vice President of Global Operations4.3yrsno data0.061%
$ 729.8k

4.3yrs

Average Tenure

56yo

Average Age

Experienced Management: AORT's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Mackin
Chairman10.1yrsUS$3.18m1.59%
$ 18.9m
James Bullock
Independent Director8.1yrsUS$217.50k0.15%
$ 1.8m
Thomas Ackerman
Independent Director20.9yrsUS$230.00k0.34%
$ 4.1m
Anthony Semedo
Independent Director3.1yrsUS$217.50k0.081%
$ 970.5k
Daniel Bevevino
Independent Director20.9yrsUS$235.00k0.34%
$ 4.1m
Jeffrey Burbank
Independent Presiding Director7.2yrsUS$265.00k0.11%
$ 1.3m
Jon Salveson
Independent Director12.5yrsUS$215.00k0.29%
$ 3.5m
Marna Borgstrom
Independent Director6.4yrsUS$220.00k0.10%
$ 1.2m
Elizabeth Hoff
Independent Director2.1yrsUS$210.00k0.060%
$ 712.1k

8.1yrs

Average Tenure

64yo

Average Age

Experienced Board: AORT's board of directors are considered experienced (8.1 years average tenure).